Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16744508 | 0.83 | SCD5 (0.52) | SCD5SMN1; SMN2HDAC4IKBKETBK1 | |
| SCHEMBL15093710 | 0.81 | SCD5 (0.57) | CHRM2CHRM4CHRM1CHRM3SCD5 | |
| SCHEMBL2759473 | 0.81 | KDM4E (0.43) | SMN1; SMN2ENPP2KDM4EALDH1A1EGFR | |
| SCHEMBL5072934 | 0.81 | PRKAA2 (0.48) | ENPP2KDM4EALDH1A1EGFRPRKAA2 | |
| SCHEMBL18623647 | 0.80 | MGLL (0.44) | ENPP2 | |
| SCHEMBL9933243 | 0.80 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3SCD5 | |
| SCHEMBL15094284 | 0.79 | MAPT (0.52) | SCD5SMN1; SMN2ALDH1A1 | |
| SCHEMBL16399556 | 0.79 | GPR119 (0.46) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL208417 | 0.77 | TLR8 (0.47) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL23922807 | 0.76 | GRM5 (0.51) | CHRM2CHRM4CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2000027790-A1 | MUTILIN COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | CHRM2 2135/4885CHRM4 2960/4885CHRM1 2022/4885 |
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | CHRM2 941/4885CHRM4 1370/4885CHRM1 480/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | CHRM2 2162/4885CHRM4 2973/4885CHRM1 2045/4885 |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | CHRM2 2135/4885CHRM4 2960/4885CHRM1 2022/4885 |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | CHRM2 2135/4885CHRM4 2960/4885CHRM1 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.